GlassScriptPhysician profile
Edie Hamilton
NPI 1992001432
$13,354.55
in general payments reported to CMS, 2019-2025
25 companies · $3,251 in 2025
The $3,251 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $922 · 2022: $1,297 · 2023: $3,734 · 2024: $4,150 · 2025: $3,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,772 · Consulting Fee: $2,050 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,772.43 |
| Consulting Fee | $2,050.00 |
| Education | $312.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,798.21 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $2,752.83 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $857.53 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $753.26 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $723.63 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $710.03 | 2022-2025 | Sotyktu |
| Amgen INC. | $706.56 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $663.79 | 2021-2025 | Dupixent |
| Ucb, INC. | $608.95 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $562.88 | 2021-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $554.73 | 2021-2025 | |
| Incyte Corporation | $380.39 | 2022-2024 | Opzelura |
| Genzyme Corporation | $252.09 | 2023-2025 | |
| Janssen Biotech, INC. | $154.77 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Organon LLC | $147.51 | 2025 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $135.41 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $125.18 | 2024-2025 | Xtrac |
| Pfizer INC. | $116.98 | 2023-2025 | |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.20 | 2023 | |
| Genentech USA, INC. | $70.10 | 2021-2025 | Xolair |
| Biofrontera INC. | $50.58 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $23.49 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.92 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edie Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.